The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Here's Why Investors Should Bet on Cooper Companies (COO) Now
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
by Zacks Equity Research
Cooper Companies' (COO) revenues across CooperVision and CooperSurgery see growth.
What's in Store for Coupa Software (COUP) in Q4 Earnings?
by Zacks Equity Research
Coupa Software (COUP) benefits from expanding customer base. Further, rising adoption of the company's platform is driving subscription services revenues and gross margin.
Cooper Companies' (COO) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Strong performance by Cooper Companies' (COO) CSI and CVI segments drove the top line in first-quarter fiscal 2019.
Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?
by Zacks Equity Research
Management at Cooper Companies (COO) expects solid contributions from CVI and CSI units.
Guidewire (GWRE) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Guidewire (GWRE) benefits from strong adoption of several cloud-based products.
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Weight Watchers (WTW) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Weight Watchers' (WTW) core Product Sales unit is expected to put up a soft show in fourth-quarter 2018.
Why Is Cooper Cos. (COO) Down 11.1% Since Last Earnings Report?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.
Stock Market News For Dec 7, 2018
by Zacks Equity Research
U.S. stock markets closed mostly lower on Thursday as arrest of Chinese tech-behemoth Huawei's CFO in Canada significantly dented investors' hope of a solution to trade-related concerns
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q4
by Zacks Equity Research
Cooper Companies (COO) gains from solid segmental performance in fiscal Q4.
Cooper Cos. (COO) Q4 Earnings Lag Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -3.04% and 0.88%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Can CVI Segment Drive Cooper Companies' (COO) Q4 Earnings?
by Zacks Equity Research
Cooper Companies (COO) is likely to gain from strong segmental show in Q4. An upbeat guidance for the quarter raises optimism.
Greif (GEF) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Greif's (GEF) fourth-quarter fiscal 2018 results are likely to be supported by favorable price-cost relationship despite elevated transportation costs.
Cooper Cos. (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cooper Cos. (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zscaler (ZS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zscaler (ZS) first-quarter fiscal 2019 results are expected to benefit from robust portfolio strength and customer wins but increasing expenses remain an overhang.
Coupa (COUP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Coupa (COUP) to benefit from expanding customer base on the back of growing adoption of spend management platform
Smartsheet (SMAR) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Smartsheet's (SMAR) third-quarter fiscal 2019 results are expected to benefit from product enhancements and customer wins but increasing expenses remain a concern.
Will HSA Member Growth Aid HealthEquity's (HQY) Q3 Earnings?
by Zacks Equity Research
HealthEquity's (HQY) top line is likely to be driven by solid Health Savings Accounts (HSA) member growth in the fiscal third quarter. However, cutthroat competition in the niche space is concerning.
Can Segmental Growth Boost Veeva Systems' (VEEV) Q3 Earnings?
by Zacks Equity Research
Veeva Systems (VEEV) likely to gain from solid segmental show in fiscal Q3; competition stiff.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal Q2 earnings likely to be marred by a soft Dental unit; Animal Health looks promising.
Why Is Cooper Cos. (COO) Up 5.1% Since Last Earnings Report?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper's MiSight Lens Effective in Checking Juvenile Myopia
by Zacks Equity Research
Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3
by Zacks Equity Research
Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.